See more : Lionheart Holdings (CUB) Income Statement Analysis – Financial Results
Complete financial analysis of Chi Sheng Pharma & Biotech Co., Ltd (4111.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chi Sheng Pharma & Biotech Co., Ltd, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Banco Santander-Chile (BSANTANDER.SN) Income Statement Analysis – Financial Results
- INSU Acquisition Corp. III (IIII) Income Statement Analysis – Financial Results
- Far Eastern International Bank Ltd. (2845.TW) Income Statement Analysis – Financial Results
- Box Ships Inc. (TEUFF) Income Statement Analysis – Financial Results
- RLH Properties, S.A.B. de C.V. (RLHPF) Income Statement Analysis – Financial Results
Chi Sheng Pharma & Biotech Co., Ltd (4111.TWO)
About Chi Sheng Pharma & Biotech Co., Ltd
Chi Sheng Pharma & Biotech Co., Ltd engages in the manufacturing, processing, sale, and import and export trade of pharmaceuticals, medical products, cosmetics, health foods, and medical equipment in Taiwan and internationally. Its products portfolio includes antibiotics and chemotherapeutic agents; plasma substitutes and amino acid preparations; water nutrients and electrolyte preparations; vitamins; hepatotropic agents; hormones and adrenal cortical steroids; autonomic nerves agents; antihistamines and antipruritics; antipyretics and analgesics; antitussives and anti-asthmas; gastro-intestinal preparations; local anesthetic preparations; hemodialysis concentrate and external solutions; peritoneal dialysis solutions; and others. The company also offers medical devices, fat emulsion products, anesthetic products, hemostatics solutions, food products, functional drinks, skin care products, and veterinary medicinal products. In addition, it offers externally applied medicines, including contact lens, salt, and iodine solutions. Chi Sheng Pharma & Biotech Co., Ltd was founded in 1962 and is headquartered in Hsinchu, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.06B | 1.14B | 1.02B | 979.36M | 1.02B |
| Cost of Revenue | 717.76M | 720.57M | 665.72M | 656.44M | 682.76M |
| Gross Profit | 343.10M | 422.51M | 356.58M | 322.92M | 340.20M |
| Gross Profit Ratio | 32.34% | 36.96% | 34.88% | 32.97% | 33.26% |
| Research & Development | 21.67M | 19.69M | 18.94M | 18.21M | 20.64M |
| General & Administrative | 51.10M | 51.72M | 46.74M | 58.88M | 69.01M |
| Selling & Marketing | 209.12M | 197.27M | 171.84M | 170.28M | 163.33M |
| SG&A | 260.22M | 248.99M | 218.59M | 229.15M | 232.35M |
| Other Expenses | 0.00 | 8.62M | 13.40M | 4.30M | 8.96M |
| Operating Expenses | 281.89M | 268.68M | 237.52M | 247.36M | 252.98M |
| Cost & Expenses | 999.65M | 989.24M | 903.24M | 903.80M | 935.74M |
| Interest Income | 0.00 | 1.36M | 417.00K | 1.73M | 1.29M |
| Interest Expense | 0.00 | 1.53M | 1.09M | 162.00K | 263.00K |
| Depreciation & Amortization | 60.67M | 72.88M | 79.08M | 84.14M | 82.53M |
| EBITDA | 149.46M | 225.20M | 197.49M | 164.58M | 178.91M |
| EBITDA Ratio | 14.09% | 20.71% | 20.73% | 16.92% | 17.60% |
| Operating Income | 61.21M | 163.81M | 132.87M | 81.60M | 97.47M |
| Operating Income Ratio | 5.77% | 14.33% | 13.00% | 8.33% | 9.53% |
| Total Other Income/Expenses | 26.12M | -1.52M | -1.10M | -171.00K | -213.00K |
| Income Before Tax | 87.33M | 162.28M | 131.78M | 81.43M | 97.26M |
| Income Before Tax Ratio | 8.23% | 14.20% | 12.89% | 8.31% | 9.51% |
| Income Tax Expense | 18.66M | -17.00M | 24.08M | 22.28M | 24.81M |
| Net Income | 68.67M | 154.01M | 80.75M | 59.14M | 72.45M |
| Net Income Ratio | 6.47% | 13.47% | 7.90% | 6.04% | 7.08% |
| EPS | 1.21 | 2.70 | 1.42 | 1.04 | 1.27 |
| EPS Diluted | 1.20 | 2.69 | 1.41 | 1.03 | 1.27 |
| Weighted Avg Shares Out | 56.98M | 56.98M | 56.98M | 56.98M | 56.98M |
| Weighted Avg Shares Out (Dil) | 57.22M | 57.32M | 57.28M | 57.22M | 57.23M |
Source: https://incomestatements.info
Category: Stock Reports